Compositions and methods for t-cell development and stimulation using designed expandable notch agonists

Soluble Notch ligand oligomer complexes with a multimeric protein scaffold enhance T cell differentiation and signaling efficiency in suspension cultures, addressing scalability and reproducibility issues of existing systems.

WO2026236276A1PCT designated stage Publication Date: 2026-11-12CHILDRENS MEDICAL CENT CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026764
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-05
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current in vitro systems for T cell generation, particularly for adoptive immunotherapy, require immobilized ligands or stromal cell co-culture for Notch signaling activation, limiting scalability and reproducibility.

Method used

Development of soluble Notch ligand oligomer complexes with a multimeric protein scaffold and Notch ligand monomers, arranged in a trans configuration to enhance inter-ligand spacing and promote receptor clustering, enabling efficient Notch signaling in suspension culture.

Benefits of technology

The oligomer complexes facilitate efficient T cell differentiation at low cell densities and in scalable systems, mimicking membrane-bound ligand presentation while maintaining the advantages of a soluble system.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000026_0000
    Figure 00000026_0000
  • Figure 00000026_0001
    Figure 00000026_0001
  • Figure 00000027_0000
    Figure 00000027_0000
Patent Text Reader

Abstract

The present disclosure provides soluble Notch ligand oligomer complexes and methods of use thereof. The oligomer complexes comprise a multimeric protein scaffold and a plurality of Notch ligand monomers, wherein the scaffold comprises one or more elongated helical regions extending outward from a core structure to present the Notch ligand monomers with increased inter-ligand spacing. The complexes are configured to induce clustering of Notch receptors and promote Notch signaling. In certain embodiments, the scaffold comprises modular helical repeat units that provide tunable spatial arrangement and trans presentation of the ligands. The Notch ligand monomers may comprise Delta-like or Jagged ligands, including DLL4, and may be operably associated with the scaffold via peptide linkers or covalent conjugation systems.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] ATTORNEY DOCKET NO. 11624-029WO1

[0002] COMPOSITIONS AND METHODS FOR T-CELL DEVELOPMENT AND STIMULATION USING DESIGNED EXPANDABLE NOTCH AGONISTS

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims benefit of U.S. Provisional Application No. 63 / 800,138. filed May 5, 2025, incorporated herein by reference in its entirety.

[0004] GOVERNMENT SUPPORT CLAUSE

[0005] This invention was made with government support under Grant Nos. DK120535 and HL007574 awarded by the National Institutes of Health. The government has certain rights in the invention.

[0006] SEQUENCE LISTING STATEMENT

[0007] The instant application contains a Sequence Listing, which has been submitted electronically in WIPO ST.26 XML format and is hereby incorporated by reference in its entirety. Said XML file, created on May 5, 2026, is named 11624-029WOl_ST26.xml and is 7,361 bytes in size. The Sequence Listing, electronically filed herewith, docs not extend beyond the scope of the specification, and does not contain new matter.

[0008] BACKGROUND

[0009] The Notch signaling pathway is a highly conserved cell-cell communication mechanism that regulates cell fate decisions across a wide range of metazoan organisms. It plays a central role in developmental biology and tissue homeostasis by controlling processes such as proliferation, differentiation, and apoptosis. The pathway is mediated through direct interaction between membrane -bound Notch receptors on one cell and their cognate ligands on an adjacent cell, making it uniquely dependent on physical cell-cell contact.

[0010] In mammals, the Notch receptor family comprises four transmembrane proteins (Notchl-4), while canonical ligands include members of the Delta- like (DLL1, DLL3, DLL4) and Jagged (JAG1, JAG2) families. Upon ligand binding, the Notch receptor undergoes a series of proteolytic cleavages, ultimately releasing the Notch intracellular domain (NICD). The NICD translocates to the nucleus, where it associates with transcriptional regulators to modulate the expression of target genes involved in lineage specification and differentiation.ATTORNEY DOCKET NO. 11624-029WO1

[0011] Notch signaling is particularly critical in the hematopoietic system, where it governs the development and maturation of multiple cell lineages. Of particular importance, Notch activation is indispensable for T cell lineage commitment from hematopoietic stem cells (HSCs). Engagement of Notch receptors by ligands such as DLL4 promotes differentiation of HSCs into early T cell progenitors and supports their progression through defined developmental stages, including the formation of CD5+CD7+progenitor T cells and subsequent maturation into CD4+CD8+double-positive T cells. In contrast, absence or inhibition of Notch signaling diverts progenitor cells toward alternative lineages, such as B cells.

[0012] Because of its essential role in T cell development, the Notch pathway has become a key target in efforts to engineer in vitro systems for T cell generation, particularly for adoptive immunotherapy applications. However, effective activation of Notch signaling in vitro has historically required immobilized ligands or stromal cell co-culture systems, reflecting the pathway’s dependence on spatially organized, multivalent ligand presentation and mechanical force generation at the receptor-ligand interface.

[0013] Accordingly, there remains a need for improved approaches to modulate Notch signaling in a controlled and scalable manner, particularly through systems that can recapitulate the structural and functional features required for efficient receptor activation.

[0014] SUMMARY OF THE INVENTION

[0015] The present disclosure provides soluble Notch ligand oligomer complexes comprising a multimeric protein scaffold and a plurality of Notch ligand monomers operably associated with the scaffold. In certain embodiments, the scaffold comprises one or more elongated helical regions extending outward from a core structure, thereby presenting the Notch ligand monomers with increased inter- ligand spacing relative to the core. The oligomer complexes are configured to induce clustering of Notch receptors and to promote Notch signaling in a population of cells.

[0016] In certain embodiments, the scaffold comprises a plurality of helical repeat units that are modular and expandable, allowing tunable control over the spatial arrangement of the Notch ligand monomers. In some embodiments, the Notch ligand monomers are presented in a trans orientation relative to the scaffold core. In certain embodiments, adjacent Notch ligand monomers are spaced apart by at least about 5 nm, 7 nm, 10 nm, or 15 nm, and the oligomer complex has an effective ligand presentation diameter of at least about 6 nm, 10ATTORNEY DOCKET NO. 11624-029WO1

[0017] nm, or 15 nm.

[0018] In certain embodiments, the oligomer complex is multivalent and comprises two or more Notch ligand monomers. The ligand monomers may be selected from Delta-like ligands (DLL1, DLL3, DLL4) or Jagged ligands (JAG1, JAG2), or functional variants thereof. In certain embodiments, the ligand comprises DLL4. The oligomer complex may be dimeric, trimeric, tetrameric, pentameric, hexameric, octameric, or a higher-order oligomer. In some embodiments, the scaffold comprises a pentameric core.

[0019] In certain embodiments, the Notch ligand monomers are linked to the scaffold via peptide linkers, including glycine-serine linkers, optionally comprising one or more repeats of Gly-Gly-Ser. In certain embodiments, the oligomer complex is assembled using a covalent conjugation system, such as a SpyTag / SpyCatcher system.

[0020] In certain embodiments, the scaffold comprises a polypeptide having at least about 80%, 90%, or 95% sequence identity to a sequence selected from SEQ ID NOs: 1-3, and the Notch ligand monomer comprises a sequence having at least about 80%, 90%, or 95% sequence identity to SEQ ID NO: 4.

[0021] In certain embodiments, the oligomer complexes promote formation of a Notch signaling synapse, mediate cell-cell bridging, and induce receptor clustering. The complexes are soluble and capable of activating Notch signaling in suspension culture.

[0022] The present disclosure further provides compositions comprising the oligomer complexes and one or more pharmaceutically acceptable carriers.

[0023] The present disclosure further provides methods of producing the oligomer complexes, comprising contacting a plurality of Notch ligand monomers with a population of scaffolds under conditions sufficient to form the complex.

[0024] The present disclosure further provides methods of activating Notch signaling in a population of cells by contacting the cells with an oligomer complex described herein. In certain embodiments, the cells are cultured in suspension and are not adhered to a substrate.

[0025] The present disclosure further provides methods of differentiating hematopoietic stem cells into T cells, comprising contacting the cells with an oligomer complex described herein. In certain embodiments, the differentiation is performed in suspension culture, in the absence of stromal cells, and / or in the absence of immobilized Notch ligand. In certain embodiments, the methods enable differentiation at low cell densities, including less than about 1 x l(P cells / mL, less than about 5 x 104cells / mL, or less than about 1 x 104cells / mE.ATTORNEY DOCKET NO. 11624-029WO1

[0026] In certain embodiments, the methods are performed in a bioreactor or other scalable culture system for large-scale production of T cells or other hematopoietic cell types.

[0027] In certain embodiments, the present disclosure further provides methods of treating a subject in need thereof by administering an effective amount of an oligomer complex described herein. In certain embodiments, the methods modulate Notch signaling in vivo, promote differentiation of progenitor cells, enhance T cell production or function, or enhance an immune response. In certain embodiments, the oligomer complex is administered alone or in combination with one or more additional therapeutic agents.

[0028] These and other embodiments of the present disclosure are encompassed within the scope of the claims.

[0029] DESCRIPTION OF DRAWINGS

[0030] Figure 1A-D shows that next-generation soluble Notch agonist C515H-DLL4 improves signal activation and T cell production. (A) PDB models showing the design of horno-pentameric protein complexes (C5) with expandable repeat protein ‘helical amis,’ with the ligand installation site represented in red dots. The number of helixes in each helical arm in C52H, C5?H, and C515H are 2, 7, and 15 respectively, and the effective spacer diameter of the trans oriented ligands are 3.3, 6.9 and 15.5 nm, as indicated. B) Flow cytometry showing mean fluorescence intensity of Notch activated U2OS-Notchl-Gal4 reporter cells for indicated concentrations of soluble C5 Notch agonists and comparison with 2D-DLL4. C) Representative flow cytometry plots, and D) corresponding histograms showing the differentiation of cord blood derived CD5+CD7+proT cells into CD4+CD8+double positive (DP) T cells using C515H-DLL4 (lOOnM) and 2D-DLL4.

[0031] Figure 2A-C shows comparison of T cell generation using various Notch agonists. CD5+CD7+cord blood derived-proT cells were differentiated to double positive (DP) CD4+CD8+T cells using soluble C3-DLL4, DLL4-mbeads, 0P9-DLL1 stromal cells, and plate-coated DLL4 (2D-DLL4). A) Representative flow cytometry plots showing DP T cells at day 28. B) Efficiency of DP T cell generation. C) C515H-DLL4 mediated differentiation of cord blood CD34+HSCs to CD4+CD8+double positive (DP) T cells in 3D suspension culture. The efficiency of C515H-DLL4 was compared with 2D-DLL4 and DLL4-microbeads-based differentiation methods.

[0032] Figure 3A-B shows the production of CD7+and CD5+CD7+double positive lymphoid progenitor cells. Cord blood derived CD34+HSCs were differentiated intoATTORNEY DOCKET NO. 11624-029WO1

[0033] lymphoid progenitor cells using different formulations of C5ISH-DLL4 Notch agonist.

[0034] Figure 4A-F shows comparison of Notch activation using different spacer lengths between the oligomeric scaffolds and the Notch ligand DLL4. A-C) Three spacer lengths were selected: lx Gly-Gly-Scr (GGS); 5x Gly-Gly-Scr (5xGGS); and lOx Gly-Gly-Scr (lOxGGS). C3, C3-HB, and C6- oligomers were conjugated with DLL4 containing different spacer lengths, and their Notch activation was tested in the U2OS-Notchl-Gal4 / UAS-H2B-Citrine cell line. Flow cytometry analysis of Notch-activated (Citrine -positive) cells was performed using A) C3-nxGGS-DLL4, B) C3-HB-nxGGS-DLL4; and C) C6-nxGGS-DLL4, where n= 1, 5, or 10. D-F) Mechanism of C515H-DLL4 mediated soluble Notch activation. D) Confocal microscopy of U2OS-Notchl cells after treatment with C5ISH-DLL4 (100 nM). Immunostaining was performed for DLL4 (green), Notchl-ECD (red), and Hoechst (blue) with (right) or without (left) treatment of C5ISH-DLL4. Cluster formation (E) and Notch synapse formation (F) in K562-Notchl-Gal4 cells induced by C5ISH-DLL4 treatment (24 h, 1 uM). Immunostaining was performed for DLL4 (green) and FLAG-Notchl (red). Scale bar = 50 micron.

[0035] DETAILED DESCRIPTION

[0036] Defiinitions

[0037] As used herein, unless otherwise defined, all technical and scientific terms have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. The term “about” when used in reference to a numerical value means within ±10% of the stated value unless otherwise specified. All ranges disclosed herein include endpoints and all intermediate values, and each endpoint is independently combinable. All numerical values are understood to be modified by the term “about,” whether explicitly stated or not.

[0038] The terms “comprising” and grammatical variants thereof are used in an open-ended sense to mean “including, but not limited to.” The terms “consisting of’ and “consisting essentially of’ are used in their conventional sense, with “consisting of’ excluding unrecited elements and “consisting essentially of’ permitting the inclusion of additional elements that do not materially affect the basic and novel characteristics of the claimed invention. The terms “a,” “an,” and “the” include both singular and plural referents unless the context clearly dictates otherwise. The term “and / or” refers to any one or more of the listed elements, individually or in combination. The terms “may,” “optionally,” and “mayATTORNEY DOCKET NO. 11624-029WO1

[0039] optionally” indicate that the subsequently described feature or element may or may not be present.

[0040] The term “subject” or “patient” refers to a human or non-human animal, including mammals such as primates, rodents, canines, felines, and livestock. A “control” refers to a standard of comparison, including a positive or negative control.

[0041] I’he terms “treat,” “treating,” or “treatment” refer to the administration of a composition or therapy to a subject for the purpose of alleviating, ameliorating, inhibiting, delaying onset of, reducing severity of, stabilizing, or preventing a disease, disorder, or condition, or one or more symptoms thereof. The terms “prevent,” “preventing,” or “prevention” refer to reducing the likelihood, delaying onset, or inhibiting the development or progression of a disease or condition in a subject. The terms “reduce,” “reducing,” “reduction,” “inhibit,” “inhibiting,” “inhibition,” “decrease,” or grammatical variants thereof refer to a measurable diminution in a biological activity, response, condition, or parameter, including partial or complete abrogation, and may include reductions of at least about 1%, 5%, 10%, 25%, 50%, 75%, 90%, or more relative to a reference or control. The term “effective amount” refers to an amount sufficient to achieve a desired biological, therapeutic, or diagnostic effect.

[0042] The terms “polypeptide,” “peptide,” or “protein” refer to a polymer of amino acids linked by peptide bonds and include full-length proteins, fragments, variants, derivatives, fusion proteins, and modified forms thereof. A “fragment” refers to a portion of a molecule that retains at least one functional or structural characteristic of the full-length molecule. A “variant” refers to a molecule that differs in sequence from a reference molecule but retains at least one functional or structural property. The term “conservatively substituted” refers to the replacement of an amino acid with another having similar physicochemical properties such that the structure or function is not substantially altered.

[0043] The term “nucleic acid” refers to DNA, RNA, or analogs thereof, including singlestranded or double- stranded forms, and includes genomic DNA, cDNA, mRNA, siRNA, miRNA, and synthetic nucleic acids. The term “isolated” refers to a material that has been removed from its natural environment or is substantially free of components with which it is naturally associated. The term “purified” refers to a material that has been enriched relative to its natural state. The term “expression” refers to transcription and / or translation of a nucleic acid into a functional product. The term “vector” refers to a nucleic acid construct capable of delivering genetic material into a host cell. The term “host cell” refers to a cellATTORNEY DOCKET NO. 11624-029WO1

[0044] into which a nucleic acid has been introduced. The term “recombinant” refers to a molecule or cell that has been engineered through manipulation of nucleic acid sequences. The term “operably linked” refers to a functional relationship between nucleic acid elements such that regulatory sequences control expression of a coding sequence.

[0045] The term “pharmaceutically acceptable” refers to a substance suitable for administration to a subject without undue toxicity or adverse effects commensurate with a reasonable benefit-risk ratio. The terms “carrier,” “excipient,” or “vehicle” refer to a substance used to facilitate formulation, administration, or delivery of an active agent. The term “composition” refers to a mixture comprising at least one active agent and optionally additional components. The term “dose” refers to a quantity administered at one time or over a defined period. The terms “administer,” “administering,” or “administration” refer to delivering a composition to a subject by any suitable route.

[0046] The term “biologically active” refers to a molecule that exhibits a detectable functional effect in a biological system. The term “modulate” refers to increasing or decreasing a measurable property or activity. The term “biomarker” refers to a measurable indicator of a biological state or condition.

[0047] The term “sequence identity” refers to the percentage of identical residues between aligned sequences over a specified region using standard algorithms. The term “substantially identical” refers to sequences having at least about 70%, 80%, 90%, 95%, 98%, or 99% identity over a defined region.

[0048] The terms “diagnose,” “diagnosing,” or “diagnosis” refer to identifying the presence or nature of a disease or condition. The term “prognosis” refers to predicting the course or outcome of a disease. The term “kit” refers to a collection of components, including reagents and instructions, for performing a method described herein. The term “instructions for use” refers to recorded guidance for practicing such methods.

[0049] The term “Notch signaling” refers to a cell-cell communication pathway mediated by interaction between a Notch receptor and a Notch ligand, resulting in proteolytic cleavage of the receptor and release of the Notch intracellular domain (NICD), which translocates to the nucleus to regulate gene expression.

[0050] The term “Notch receptor” refers to any member of the Notch receptor family, including Notchl, Notch2, Notch3, and Notch4, or functional variants or fragments thereof capable of participating in Notch signaling.ATTORNEY DOCKET NO. 11624-029WO1

[0051] The term “Notch ligand” refers to a protein capable of binding and activating a Notch receptor, including Delta-like ligands (DLL1, DLL3, DLL4) and Jagged ligands (JAG1, JAG2), as well as functional fragments, variants, or engineered forms thereof.

[0052] The term “Notch ligand monomer” refers to a single polypeptide unit comprising a Notch ligand or a functional portion thereof that is capable of engaging a Notch receptor.

[0053] 1’he term “oligomer” or “oligomeric complex” refers to a structure comprising two or more subunits, including dimers, trimers, tetramers, pentamers, hexamers, and higher-order assemblies.

[0054] The term “scaffold” refers to a protein or molecular framework that supports the spatial arrangement of one or more Notch ligand monomers and may be naturally occurring or synthetically designed.

[0055] The term “multimeric scaffold” refers to a scaffold comprising multiple repeating or symmetric subunits arranged in a defined oligomeric state.

[0056] The term “helical repeat unit” refers to a structural motif comprising one or more a-helices that can be repeated or concatenated to extend the length of a protein structure.

[0057] The term “expandable helical scaffold” refers to a scaffold comprising modular helical repeat units that can be added to increase the size, length, or radial dimensions of the scaffold.

[0058] The term “elongated helical region” refers to a portion of a scaffold comprising one or more a-helices arranged to extend outward from a core structure.

[0059] The term “core structure” refers to a central region of a scaffold, typically comprising a symmetric oligomeric assembly from which other structural elements extend.

[0060] The term “trans presentation” refers to an arrangement in which ligand moieties are positioned outward from a central scaffold such that they are spatially separated and oriented away from the core, enabling interaction with receptors on separate cells.

[0061] The term “cis presentation” refers to an arrangement in which ligand moieties are positioned close to or within the scaffold core and are not substantially extended outward.

[0062] The term “inter- ligand spacing” refers to the distance between adjacent ligand molecules within an oligomeric complex.

[0063] The term “ligand presentation diameter” refers to the effective diameter defined by the spatial arrangement of ligand molecules within an oligomeric complex.

[0064] The term “multivalent” refers to the presence of multiple ligand units within a single complex capable of engaging multiple receptors simultaneously.ATTORNEY DOCKET NO. 11624-029WO1

[0065] The term “cell-cell bridging’’ refers to the ability of a molecule or complex to simultaneously bind receptors on two or more cells, thereby bringing the cells into proximity.

[0066] The term “receptor clustering” refers to the aggregation of receptors on a cell surface induced by multivalent ligand binding.

[0067] fhe term “Notch synapse” refers to a localized interface between interacting cells in which Notch receptors and ligands are clustered to facilitate signaling.

[0068] The term “soluble,” in the context of a Notch ligand or complex, refers to a molecule that is not membrane-bound and is capable of functioning in solution.

[0069] The term “suspension culture” refers to a cell culture system in which cells are not adhered to a surface and are maintained in a liquid medium.

[0070] The term “hematopoietic stem cell” or “HSC” refers to a multipotent stem cell capable of giving rise to blood cell lineages.

[0071] The term “T cell differentiation” refers to the process by which hematopoietic stem cells or progenitor cells develop into T lymphocytes, including intermediate stages such as CD7+cells, CD5+CD7+progenitor T cells, and CD4+CD8+double-positive T cells.

[0072] The term “low cell density” refers to a culture condition in which cells arc present at a concentration insufficient to promote efficient signaling through cell-cell contact alone.

[0073] The term “bioreactor” refers to a system or device that supports biologically active environments for cell growth and / or differentiation under controlled conditions.

[0074] The term “SpyTag” refers to a peptide capable of forming a covalent bond with a SpyCatcher protein domain.

[0075] The term “SpyCatcher” refers to a protein domain capable of forming a covalent bond with a SpyTag peptide.

[0076] The term “fusion protein” refers to a polypeptide comprising two or more protein domains joined together, including combinations of scaffold components and ligand components.

[0077] General Description

[0078] Notch ligands are indispensable for T cell differentiation, and current in vitro T cell differentiation protocols utilize either mouse stromal cells expressing Notch ligands or plate-bound ligands, such as DLL4, to activate Notch signaling. These approaches rely on surface-immobilized or cell-associated ligand presentation to achieve sufficient receptorATTORNEY DOCKET NO. 11624-029WO1

[0079] clustering and activation. While effective, such systems present significant limitations for scalability, reproducibility, and clinical translation, particularly in the context of large-scale manufacturing of T cells for adoptive immunotherapy. A soluble form of a Notch ligand, such as DLL4, provides a potential alternative to plate-bound or stromal cell-based systems, enabling suspension culture and compatibility with bioreactor-based processes. However, soluble monomeric or weakly multimerized Notch ligands generally exhibit reduced signaling efficiency due to insufficient receptor clustering and lack of appropriate spatial organization.

[0080] Previously, engineered multimeric Notch ligand complexes, including trimeric assemblies such as C3-DLL4, were developed to enhance Notch activation in solution. While such constructs demonstrated improved activity relative to monomeric ligands and enabled some degree of T cell differentiation in suspension culture, their efficiency remained inferior to that achieved using plate-bound ligands or stromal cells expressing Notch ligands. These limitations are believed to arise from inadequate spatial arrangement, suboptimal ligand spacing, and insufficient ability to induce receptor clustering and cell-cell bridging in solution.

[0081] The present disclosure provides compositions and methods that overcome these limitations through the use of engineered multimeric protein scaffolds that spatially organize Notch ligand monomers in a controlled and tunable manner. In particular, the invention provides soluble Notch ligand oligomer complexes comprising a multimeric protein scaffold and a plurality of Notch ligand monomers operably associated with the scaffold. The scaffold comprises one or more elongated helical regions extending outward from a core structure, thereby presenting the Notch ligand monomers with increased interligand spacing relative to the core. This configuration enables enhanced multivalent engagement of Notch receptors, improved receptor clustering, and increased signaling potency.

[0082] In certain embodiments, the scaffold comprises a multimeric assembly having defined symmetry, including but not limited to dimeric, trimeric, tetrameric, pentameric, hexameric, octameric, or higher-order oligomeric states. In some embodiments, the scaffold comprises a pentameric core structure. The scaffold may comprise naturally occurring protein domains, engineered protein domains, or de novo designed protein structures. In preferred embodiments, the scaffold comprises de novo designed helical repeat proteins arranged to form a multimeric core with outwardly extending helical arms.ATTORNEY DOCKET NO. 11624-029WO1

[0083] In certain embodiments, the scaffold comprises a plurality of helical repeat units that are modular and expandable. These helical repeat units may be arranged in tandem to form elongated helical regions that extend radially outward from the core structure. The number of helical repeat units may be varied to tunc the spatial configuration of the complex. For example, the scaffold may comprise at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more helices per arm, or any value or range therebetween. Increasing the number of helical repeat units results in increased radial extension and greater inter-ligand spacing.

[0084] In certain embodiments, the Notch ligand monomers are presented in a trans configuration relative to the scaffold core, such that the ligands are oriented outward and spatially separated from one another. In contrast to cis presentation, in which ligands are closely associated with the core, trans presentation enables more effective interaction with receptors on adjacent cells and facilitates multivalent engagement across cell surfaces.

[0085] In certain embodiments, the inter- ligand spacing between adjacent Notch ligand monomers is at least about 3 nm, 4 nm, 5 nm, 6 nm, 7 nm, 8 nm, 9 nm, 10 nm, 11 nm, 12 nni, 13 nm, 14 nm, or 15 nm, or within a range defined by any two of these values. In certain embodiments, the effective ligand presentation diameter of the oligomer complex is at least about 5 nm, 7 nm, 10 nm, or 15 nm. Without being bound by theory, increasing inter-ligand spacing enhances the ability of the complex to bridge cells and to cluster Notch receptors at the cell surface, thereby promoting efficient Notch signaling.

[0086] In certain embodiments, the oligomer complex is multivalent, comprising two or more Notch ligand monomers. In some embodiments, the complex comprises at least 3, 4, 5, 6, 7, 8, or more ligand monomers. The ligand monomers may be identical or different and may be selected from DLL1, DLL3, DLL4, JAG1, JAG2, or functional variants thereof. In preferred embodiments, the ligand comprises DLL4.

[0087] In certain embodiments, the Notch ligand monomers are linked to the scaffold via peptide linkers. Such linkers may comprise flexible or semi-flexible sequences, including glycine-serine linkers. In certain embodiments, the linker comprises one or more repeats of Gly-Gly-Ser. The length of the linker may be selected to provide sufficient flexibility while maintaining the desired spatial orientation of the ligand.

[0088] In certain embodiments, the oligomer complex is assembled using a covalent or non-covalent conjugation system. In some embodiments, the Notch ligand monomer comprises a SpyTag moiety and the scaffold comprises a Spy Catcher moiety, enabling covalent bond formation between the ligand and scaffold. Other conjugation systems may also be used.ATTORNEY DOCKET NO. 11624-029WO1

[0089] Sequences

[0090] In certain embodiments, the compositions described herein comprise one or more polypeptide sequences corresponding to engineered scaffold proteins and Notch ligand components. In particular embodiments, the scaffold comprises an expandable oligomeric protein selected from SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and the Notch ligand component comprises a sequence corresponding to SEQ ID NO: 4, or a functional fragment or variant thereof.

[0091] SEQ ID NOs: 1-3 correspond to expandable oligomeric scaffold proteins comprising multimeric core structures and one or more elongated helical regions formed from repeating helical units. These sequences are designed to form oligomeric assemblies, including pentameric structures, capable of presenting attached ligands in a defined spatial arrangement. In certain embodiments, SEQ ID NO: 1 corresponds to a scaffold comprising a minimal number of helical units, while SEQ ID NO: 2 and SEQ ID NO: 3 comprise progressively increased numbers of helical repeat units, resulting in increased radial extension and ligand spacing. In preferred embodiments, SEQ ID NO: 3 provides an extended scaffold capable of achieving enhanced Notch activation due to increased interligand spacing and trans presentation.

[0092] SEQ ID NO: 4 corresponds to a Notch ligand polypeptide, such as a DLL4-derived sequence, optionally fused to a peptide tag (e.g., SpyTag) and / or purification tag (e.g., His-tag). In certain embodiments, the Notch ligand sequence comprises the extracellular domain of DLL4 or a functional fragment thereof capable of binding and activating a Notch receptor.

[0093] In certain embodiments, the scaffold polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 1-3, or a fragment thereof, provided that the resulting scaffold retains the ability to form a multimeric assembly and to present ligands in an extended configuration. In certain embodiments, the Notch ligand polypeptide comprises a sequence having at least about 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to SEQ ID NO: 4, or a fragment thereof, provided that the resulting polypeptide retains the ability to bind and activate a Notch receptor.

[0094] Sequence identity may be determined over the full length of the sequence or over a functionally relevant portion thereof using standard alignment algorithms known in the art. In certain embodiments, substitutions within the sequence are conservative substitutions thatATTORNEY DOCKET NO. 11624-029WO1

[0095] do not substantially alter the structure or function of the polypeptide. In other embodiments, non-conservative substitutions, insertions, deletions, or truncations may be present, provided that the resulting variant retains at least one functional property, including oligomerization, ligand presentation, receptor binding, or Notch activation.

[0096] In certain embodiments, the scaffold and ligand components are used in combination to form a soluble Notch ligand oligomer complex. The scaffold polypeptide may comprise a binding domain, such as SpyCatcher, that is capable of forming a covalent bond with a complementary tag, such as SpyTag, present on the ligand polypeptide. In such embodiments, SEQ ID NOs: 1-3 may comprise a SpyCatcher fusion, and SEQ ID NO: 4 may comprise a SpyTag fusion, thereby enabling site-specific conjugation of the ligand to the scaffold.

[0097] In certain embodiments, the ratio of ligand polypeptide to scaffold subunits is selected to achieve a desired level of ligand valency. For example, in a pentameric scaffold, up to five ligand molecules may be conjugated per scaffold complex. In certain embodiments, the degree of ligand loading is at least about 50%, 60%, 70%, 80%, 90%, or 100% of available binding sites.

[0098] In certain embodiments, the combination of scaffold sequence and ligand sequence results in an oligomer complex having defined structural and functional properties, including increased inter-ligand spacing, trans presentation of ligands, and enhanced ability to induce receptor clustering and Notch signaling. Variants of the scaffold and ligand sequences that preserve these properties are encompassed within the scope of the invention.

[0099] In certain embodiments, the scaffold and ligand sequences may be encoded by nucleic acids and expressed recombinantly in a host cell. The sequences may be optimized for expression, stability, solubility, or other desirable properties. In some embodiments, the sequences may include additional elements, such as signal peptides, purification tags, cleavage sites, or linker sequences.

[0100] In certain embodiments, fragments of SEQ ID NOs: 1-4 may be used, provided that such fragments retain functional activity. For example, a fragment of a scaffold sequence that retains the ability to oligomerize and present ligands in an extended configuration may be used. Similarly, a fragment of a Notch ligand sequence that retains receptor-binding and activation capability may be used.

[0101] In certain embodiments, combinations of different scaffold variants and ligand variants may be employed to tune the properties of the oligomer complex, including ligandATTORNEY DOCKET NO. 11624-029WO1

[0102] spacing, valency, and signaling activity. Such combinations are within the scope of the present disclosure.

[0103] The sequences disclosed herein, including SEQ ID NOs: 1-4 and variants thereof, provide a modular platform for constructing soluble Notch ligand oligomer complexes with tunable structural and functional properties suitable for use in cell signaling, differentiation, and therapeutic applications.

[0104] Methods of Use

[0105] The oligomer complexes described herein are configured to induce clustering of Notch receptors and to promote Notch signaling in target cells. In certain embodiments, the complexes promote formation of a Notch synapse and mediate cell-cell bridging by simultaneously engaging receptors on adjacent cells. These properties enable efficient activation of Notch signaling in suspension culture systems.

[0106] The present disclosure further provides compositions comprising the oligomer complexes described herein and, optionally, one or more pharmaceutically acceptable carriers, excipients, or diluents.

[0107] The present disclosure further provides methods of producing the oligomer complexes described herein. In certain embodiments, such methods comprise contacting a plurality of Notch ligand monomers with a population of scaffolds under conditions sufficient to promote formation of the oligomer complex. In some embodiments, the ligand monomers and scaffolds are recombinantly expressed and subsequently combined to form the complex.

[0108] The present disclosure further provides methods of activating Notch signaling in a population of cells. In certain embodiments, such methods comprise contacting the population of cells with a soluble Notch ligand oligomer complex as described herein. The cells may be cultured in suspension or adherent conditions. In preferred embodiments, the cells are cultured in suspension and are not adhered to a substrate.

[0109] In certain embodiments, the methods are used to differentiate hematopoietic stem cells (HSCs) into T cells. Such methods may comprise contacting HSCs with the oligomer complexes described herein under conditions sufficient to promote differentiation into T cell lineages. In certain embodiments, the differentiation is perfomied in suspension culture, in the absence of stromal cells, and / or in the absence of immobilized Notch ligand.ATTORNEY DOCKET NO. 11624-029WO1

[0110] In certain embodiments, the methods enable differentiation at low cell densities, such as less than about 1 x 103cells / mL, less than about 5 x 104cells / mL, or less than about 1 x 104cells / mL. The ability to activate Notch signaling under such conditions represents a significant advantage over prior systems, which rely on high cell density or surface presentation.

[0111] In certain embodiments, the methods are performed in a bioreactor or other scalable culture system. Such systems may be used for large-scale production of T cells for therapeutic applications, including adoptive cell therapy. The compositions and methods described herein may also be used for the generation of other hematopoietic cell types, including NK cells and progenitor cells.

[0112] Without being bound by theory, the enhanced activity of the oligomer complexes described herein is attributed to the controlled spatial arrangement of Notch ligand monomers, which enables efficient receptor clustering, cell-cell bridging, and formation of signaling synapses in solution. This engineered architecture recapitulates key features of membrane-bound ligand presentation while retaining the advantages of a soluble system.

[0113] In certain embodiments, the present disclosure provides methods of treating a subject in need thereof by administering an effective amount of a soluble Notch ligand oligomer complex as described herein. The oligomer complexes of the present disclosure are capable of modulating Notch signaling in vivo and may be used to influence cell fate decisions, immune function, and tissue homeostasis.

[0114] In certain embodiments, the methods comprise administering to a subject an oligomer complex configured to induce clustering of Notch receptors and promote Notch signaling in a population of cells within the subject. The modulation of Notch signaling may include activation, enhancement, or regulation of the pathway, depending on the biological context and therapeutic objective.

[0115] In certain embodiments, the subject has a condition associated with impaired, insufficient, or dysregulated Notch signaling. Such conditions may include immunodeficiencies, hematological disorders, malignancies, or other diseases in which Notch signaling plays a regulatory role. In certain embodiments, administration of the oligomer complex results in increased Notch pathway activation relative to a control or baseline condition.

[0116] In certain embodiments, the methods promote differentiation of progenitor or stem cells in vivo. In particular embodiments, the oligomer complexes are used to promoteATTORNEY DOCKET NO. 11624-029WO1

[0117] differentiation of hematopoietic stem cells (HSCs) into lymphoid lineages, including T cells. In certain embodiments, administration of the oligomer complex increases the production, maturation, or function of T cells in the subject.

[0118] In certain embodiments, the subject has an immunodeficiency or a condition requiring immune reconstitution. In such embodiments, administration of the oligomer complex enhances immune cell development and / or function. In other embodiments, the subject has cancer, and the methods enhance an anti-tumor immune response, for example by increasing T cell production, activation, or persistence.

[0119] In certain embodiments, the oligomer complex is administered systemically. In other embodiments, the oligomer complex is administered locally to a target tissue or site.

[0120] Suitable routes of administration include, but are not limited to, intravenous, subcutaneous, intramuscular, intraperitoneal, or intratumoral administration. The oligomer complex may be formulated in a pharmaceutically acceptable composition comprising one or more carriers, excipients, or stabilizing agents.

[0121] In certain embodiments, the administered oligomer complex comprises a scaffold polypeptide having at least about 80%, 90%, or 95% sequence identity to any one of SEQ ID NOs: 1-3 and a Notch ligand polypeptide having at least about 80%, 90%, or 95% sequence identity to SEQ ID NO: 4. In certain embodiments, the oligomer complex retains the ability to induce receptor clustering and Notch signaling following administration in vivo.

[0122] In certain embodiments, the oligomer complex is administered in combination with one or more additional therapeutic agents. Such agents may include, but are not limited to, chemotherapeutic agents, immune checkpoint inhibitors, cytokines, growth factors, or cellbased therapies. In certain embodiments, the cell-based therapy comprises adoptive transfer of T cells. In some embodiments, the T cells administered to the subject have been expanded or differentiated ex vivo using the oligomer complexes described herein prior to administration.

[0123] In certain embodiments, the methods described herein result in a measurable biological effect, including increased Notch signaling, increased receptor clustering, enhanced immune cell production, or improved therapeutic outcomes relative to a control. The magnitude of such effects may vary depending on dose, route of administration, and the condition being treated.ATTORNEY DOCKET NO. 11624-029WO1

[0124] In certain embodiments, the oligomer complexes are administered at a dose sufficient to achieve a therapeutic effect without undue toxicity. Dosage may be determined based on factors including the subject’s condition, age, weight, and response to treatment. In certain embodiments, the oligomer complex is administered as a single dose or as multiple doses over a defined treatment period.

[0125] In certain embodiments, the subject is a human. In other embodiments, the subject is a non-human animal, including a mammal used in veterinary or research applications.

[0126] It will be understood that the therapeutic methods described herein may be modified or optimized based on the specific application, and that various combinations of the features described herein are contemplated within the scope of the present disclosure.

[0127] It will be apparent to those skilled in the art that various modifications and variations can be made in the present disclosure without departing from the scope or spirit of the invention. Other embodiments will be apparent from consideration of the specification and practice of the methods disclosed herein. The specification and examples are to be considered as exemplary only, with the true scope and spirit of the invention being indicated by the following claims.

[0128] EXAMPLES

[0129] Example 1: Method of designing oligomeric proteins with helical expansion The design of expandable helical oligomers in this invention involves a modular, computational strategy using de novo designed helical repeat proteins (DHRs) as building blocks. Protein oligomers, such as pentamers (C5 symmetry), were engineered which are composed of core a-helical bundles (see example in Figure 1 A). These core bundles were then extended by sequentially adding identical two-helix ‘hairpin’ units derived from the DIIR — one hairpin at a time. This iterative addition enabled the formation of elongated helical arms. A key feature of this design is the ability to control the oligomer's spatial configuration by extending the arms at the N-terminus, allowing precise modulation of their architecture. For detailed sequences of these expandable oligomers, please refer to the corresponding section.

[0130] Example 2: A designed rigid pentameric soluble Notch agonist has increased potencyATTORNEY DOCKET NO. 11624-029WO1

[0131] It was previously found (PCT WO2024 / 076499, herein incorporated by reference in its entirety for its teaching concerning methods and compositions for T-cell differentiation), that the trimeric C3-DLL4 form is the most effective Notch agonist, but it was less efficient than 2D-DLL4 in stimulating T cell differentiation.

[0132] It has now been discovered that different lengths of a flexible linker had little effect on the overall efficiency of reporter cell activation and it was found (Figure 4A-C) that extending the spacing of ligand with more rigid linkers was able to augment both the bridging and clustering efficiency of a soluble Notch agonist at the Notch synapse. De novo designed oligomeric helical bundles that present cis- termini but whose arms can be extended outward with repeat helical proteins were tested, thus turning the oligomer into a trans- ligand presenting complex (Figure 1A). A previously designed pentameric (C5) helical bundle was used as starting place for its ability to install expandable arms, as well as for its increased valency which could facilitate improved binding to cells. The core C5 contains only 2 helices per monomer (C52H) and consequently acts as a cis- ligand presenting oligomer, whereas C5 containing 7 and 15 helixes (C5TH and C5I.5H) represent trans- presenting oligomers. The diameter of the ligand-presenting surface of these assemblies increases with the arm length (C52H = 3.3 nm; C5?H = 6.9 nm; and C5ISH = 15.5 nm; compared to C3 = 5.9 nm), increasing the ligand-to-ligand distance and providing more space for ligand-receptor interactions at cell-cell junctions at longer arm lengths (Figure 1A). DLL4 was conjugated to these isomers and tested their efficacies in Notch activation using the U2OS-Notchl-Gal4 reporter cell line. As predicted, Notch activation increased as the length of helical arms increased, with C5ISH comparable to 2D-DLL4 as an activator in this assay (Figure IB). C5ISH-DLL4 induces cell-cell bridging, receptor clustering, and Notch synapse formation in U2OS-Notchl-Gal4 and K562-Notchl-Gal4 cells, as judged by immunostaining and confocal microscopy (Figure 4D-F).

[0133] C515H-DLL4 was used in an assay for differentiation of cord blood CD34+IISCs in suspension culture to CD5+CD7+proT cells and subsequently to CD4+CD8+DP T cells. At the optimal dose (100 nM), C5ISH-DLL4 supported the generation of DP T cells more efficiently than 2D-DLL4 and DLL4-pbeads, a significant improvement over C3-DLL4 (Figure 1C-D). Thus, C5ISH-DLL4 represents a highly efficient soluble Notch agonist that outperforms 2D-DLL4-based differentiation.

[0134] Example 3: Comparison of C5ISH-DLL4 method with our previous C3-DLL4 method for T cell differentiation in 3D suspension culture.ATTORNEY DOCKET NO. 11624-029WO1

[0135] T cell differentiation from CD34+hematopoietic stem cells (HSCs) to CD4+CD8+double-positive (DP) T cells occur in two major steps, each lasting approximately 14 days. In the first step (day 0-14), CD34+HSCs differentiate into CD5+CD7+DP progenitor T cells (proT cells) via an intermediate CD7+lymphoid progenitor stage. In the second step (day 14-28), proT cells further differentiate into CD4+CD8+DP T cells.

[0136] A previous soluble Notch agonist C3-DLL4 failed to effectively support the first differentiation step in cord blood HSCs. Since soluble Notch activation requires agonist-mediated cell-cell bridging, and the starting cell number at day 0 is extremely low (10 x 103cells / mL), it was reasoned that the poor efficiency observed in the first step is due to the low initial cell density. However, in the second step, the starting cell number increases (100 x 103cells / mL), resulting in CD4+CD8+DP T cell in suspension culture, although the yield is 25-30% of the 2D-DLL4 method (Figure 2).

[0137] To improve efficiency, a superior Notch agonist, C5ISH-DLL4, was designed. In the first step, cord blood HSC differentiation in suspension culture supported by C ISH-DLL4 produced CD7+lymphoid progenitor cells at efficiencies comparable to 2D methods and CD5+CD7+proT cells with slightly lower efficiency (Figure 3) - a marked improvement over C3-DLL4. Similarly, in the second step, the percentage of CD4+CD8+DP T cells in the C515H-DLL4 (100 nM) condition was higher than in the 2D-DLL4 method (Figure 1 and 2).

[0138] In conclusion, C5ISH-DLL4 is a highly efficient Notch agonist that supports HSC differentiation into T cells in 3D suspension culture, achieving efficiencies comparable to existing 2D methods.ATTORNEY DOCKET NO. 11624-029WO1

[0139] SEQUENCES

[0140] Protein sequence of Expandable C5 oligomers (fused to Spy Catcher):

[0141] >C52H-SpyCatcher SEQ ID NO: 1 MHHHHHHGSDSATHIKFSKRDIDGKELAGATMELRDSSGKTISTWISDGQVKDFYLMP GKYTFVETAAPDGYEIATAITFTVNEQGQVTVNGKATKGGGSTRRKQEMKREKKEME KIREETEEVKKEIEESKKRPQSESAKNLILIMQLLINQIRLLALQIRMLALQLQE

[0142] >C57H-Spy Catcher SEQ ID NO: 2 MHHHHHHGSDSATHIKFSKRDIDGKELAGATMELRDSSGKTISTWISDGQVKDFYLMP GKYTFVETAAPDGYEIATAITFTVNEQGQVTVNGKATKGGGSSDLQEVADRIVEQLKR EGRSPEEARKEARRLIEEIKQSAGGDSELIEVAVRIVKFLEEAGMSPSEAAKVAVELIERI RRAAGGDSELIEKAVRIVRRLERRGLSPAEAAKIAVAIIAAEVLSREAEKIREETEEVKK EIEESKKRPQSESAKNLILIMQLLINQIRLLALQIQMLRLQLEL

[0143] >C5i5H-SpyCatcher SEQ ID NO: 3 MHHHHHHGSDSATHIKFSKRDIDGKELAGATMELRDSSGKTISTWISDGQVKDFYLMP GKYTFVETAAPDGYEIATAITFTVNEQGQVTVNGKATKGGGSSDLQEVADRIVEQLKR EGRSPEEARKEARRLIEEIKQSAGGDSELIEVAVRIVKELEEQGRSPSEAAKEAVELIERI RRAAGGDSELIEVAVRIVKELEEQGRSPSEAAKEAVELIERIRRAAGGDSELIEVAVRIV KELEEQGRSPSEAAKEAVELIERIRRAAGGDSELIEVAVRIVKELEEQGRSPSEAAKEAV ELIERIRRAAGGDSELIEVAVRIVKFLEEAGMSPSEAAKVAVELIERIRRAAGGDSELIEK AVRIVRRLERRGLSPAEAAKIAVAIIAAEVLSREAEKIREETEEVKKEIEESKKRPQSESA KNLILIMQLLINQIRLLALQIQMLRLQLEL

[0144] Protein sequence of DLL4-SpyTag:

[0145] >DLL4(l-405)-GS-SpyTag-6xHIS SEQ ID NO: 4 MAAASRSASGWALLLLVALWQQRAAGSGVFQLQLQEF1NERGVLASGRPCEPGCRTF FRVCLKHFQAVVSPGPCTFGTVSTPVLGTNSFAVRDDSSGGGRNPLQLPFNFTWPGTFS LIIEAWHAPGDDLRPEALPPDALISKIAIQGSLAVGQNWLLDEQTSTLTRLRYSYRVICS DNYYGDNCSRLCKKRNDHFGHYVCQPDGNLSCLPGWTGEYCQQPICLSGCHEQNGY CSKPAECLCRPGWQGRLCNECIPHNGCRHGTCSTPWQCTCDEGWGGLFCDQDLNYCT HHSPCKNGATCSNSGQRSYTCTCRPGYTGVDCELELSECDSNPCRNGGSCKDQEDGY HCLCPPGYYGLHCEHSTLSCADSPCFNGGSCRERNQGANYACECPPNFTGSNCEKKGS AHIVMVD A YKPTKGS GHHHHHH

Claims

ATTORNEY DOCKET NO. 11624-029WO1CLAIMSWhat is claimed is:

1. A soluble Notch ligand oligomer complex comprising:(a) a multimcric protein scaffold; and(b) a plurality of Notch ligand monomers operably associated with the scaffold; wherein the scaffold comprises one or more elongated helical regions extending outward from a core structure, such that the Notch ligand monomers are presented with increased inter-ligand spacing relative to the core structure.

2. A soluble Notch ligand oligomer complex comprising a plurality of Notch ligand monomers and a scaffold, wherein the complex is configured to:(a) induce clustering of Notch receptors on a target cell; and(b) promote Notch signaling in the target cell,wherein at least one Notch ligand monomer comprises a helical protein structure.

3. A soluble Notch ligand oligomer complex comprising at least one Notch ligand monomer and a scaffold, wherein at least one Notch ligand monomer comprises at least three helices and is positioned on the scaffold to enable multivalent receptor engagement.

4. The oligomer complex of any one of claims 1-3, wherein the scaffold comprises a plurality of helical repeat units.

5. The oligomer complex of claim 4, wherein the helical repeat units are modular and increase the radial extension of the scaffold.

6. The oligomer complex of any one of claims 1-5, wherein the Notch ligand monomers are presented in a trans orientation relative to the scaffold core.

7. The oligomer complex of any one of claims 1-6, wherein adjacent Notch ligand monomers are spaced apart by at least about 5 nm.

8. The oligomer complex of claim 7, wherein the spacing is at least about 7 nm, 10 nm, or 15 nm.

9. The oligomer complex of any one of claims 1-8, wherein the complex has an effective ligand presentation diameter of at least about 6 nm.

10. The oligomer complex of claim 9, wherein the diameter is at least about 10 nm or about 15 nm.ATTORNEY DOCKET NO. 11624-029WO111. The oligomer complex of any one of claims 1-10, wherein the complex is dimeric, trimeric, tetrameric, pentameric, hexameric, octameric, icosahedral, or a higher- order oligomer.

12. The oligomer complex of any one of claims 1-11, wherein the scaffold comprises a pentameric core.

13. The oligomer complex of any one of claims 1-12, wherein the Notch ligand monomer is selected from the group consisting of Delta-like- 1 (DLL1), Delta-like-3 (DLL3), Delta-like-4 (DLL4), Jagged 1 (JAG1), and Jagged 2 (JAG2).

14. The oligomer complex of claim 13, wherein the Notch ligand monomer comprises DLL4.

15. The oligomer complex of any one of claims 1-14, wherein the complex comprises a single type of Notch ligand monomer.

16. The oligomer complex of any one of claims 1-14, wherein the complex comprises at least two types of Notch ligand monomers.

17. The oligomer complex of any one of claims 1-16, wherein the Notch ligand monomers are linked to the scaffold via a peptide linker.

18. The oligomer complex of claim 17, wherein the linker comprises a glycinc-scrinc (GS) linker.

19. The oligomer complex of claim 18, wherein the linker comprises one or more repeats of Gly-Gly-Ser.

20. The oligomer complex of any one of claims 1-1 , wherein the Notch ligand monomers are fused to a SpyTag.

21. The oligomer complex of any one of claims 1-20, wherein the scaffold is fused to a SpyCatcher.

22. The oligomer complex of any one of claims 1-21, wherein the complex is formed via SpyTag / SpyCatcher interaction.

23. The oligomer complex of any one of claims 1-22, wherein the scaffold comprises a polypeptide having at least 80%, 90%, or 95% sequence identity to a sequence selected from SEQ ID NOs: 1-3.

24. The oligomer complex of claim 23, wherein the scaffold comprises a sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.ATTORNEY DOCKET NO. 11624-029WO125. The oligomer complex of any one of claims 1-24, wherein the Notch ligand monomer comprises a sequence having at least 80%, 90%, or 95% identity to SEQ ID NO: 4.

26. The oligomer complex of claim 25, wherein the Notch ligand monomer comprises SEQ ID NO: 4.

27. I’he oligomer complex of any one of claims 1-26, wherein the complex promotes formation of a Notch signaling synapse.

28. The oligomer complex of any one of claims 1-27, wherein the complex mediates cell-cell bridging.

29. The oligomer complex of any one of claims 1-28, wherein the complex induces receptor clustering detectable by microscopy or reporter assay.

30. A composition comprising the oligomer complex of any one of claims 1-29 and a pharmaceutically acceptable carrier.

31. A method of producing a soluble Notch ligand oligomer complex, comprising contacting a plurality of Notch ligand monomers with a population of scaffolds under conditions sufficient to form the complex.

32. The method of claim 31, wherein the Notch ligand monomers comprise a SpyTag and the scaffolds comprise a SpyCatcher.

33. The method of claim 31 or 32, wherein the scaffold comprises repeating helical units that extend outward from a core structure.

34. A method of activating Notch signaling in a population of cells, comprising contacting the population of cells with the oligomer complex of any one of claims 1-29.

35. The method of claim 34, wherein the cells are in suspension culture.

36. The method of claim 34 or 35, wherein the cells are not adhered to a substrate.

37. The method of any one of claims 34—36, wherein the contacting induces receptor clustering and Notch pathway activation.

38. A method of differentiating hematopoietic stem cells into T cells, comprising contacting the cells with the oligomer complex of any one of claims 1-29.

39. The method of claim 38, wherein the differentiation is performed in suspension culture.

40. The method of claim 38 or 39, wherein the differentiation occurs in the absence of stromal cells.ATTORNEY DOCKET NO. 11624-029WO141. The method of any one of claims 38-40, wherein the differentiation occurs in the absence of immobilized Notch ligand.

42. The method of any one of claims 38-41, wherein the hematopoietic stem cells differentiate into CD5+CD7+progenitor T cells.

43. The method of any one of claims 38-42, wherein the cells further differentiate into CD4+CD8+double-positive T cells.

44. The method of any one of claims 34-43, wherein the contacting is performed at a cell density of less than about 1 x 105cells / mL.

45. The method of claim 44, wherein the cell density is less than about 5 x 104cells / mL or about 1 x 104cells / mL.

46. The method of any one of claims 34-45, wherein the contacting is performed in a bioreactor.

47. The method of claim 46, wherein the method is used for large-scale production of T cells for therapeutic use.

48. A method of treating a subject in need thereof, comprising administering to the subject an effective amount of the oligomer complex of any one of claims 1-30.

49. The method of claim 48, wherein the treatment comprises modulating Notch signaling in a population of cells in the subject.

50. The method of claim 48 or 49, wherein the subject has a condition associated with impaired or dysregulated Notch signaling.

51. The method of any one of claims 58-50, wherein the oligomer complex induces clustering of Notch receptors in cells of the subject.

52. The method of any one of claims 48-51, wherein the oligomer complex promotes differentiation of progenitor cells in the subject.

53. The method of any one of claims 48-52, wherein the progenitor cells comprise hematopoietic stem cells.

54. The method of claim 53, wherein the hematopoietic stem cells are induced to differentiate into T cells in vivo.

55. The method of any one of claims 48-54, wherein the treatment enhances T cell production or function in the subject.

56. The method of any one of claims 48-55, wherein the subject has an immunodeficiency or a condition requiring immune reconstitution.ATTORNEY DOCKET NO. II624-029WO157. The method of any one of claims 48-56, wherein the subject has cancer and the treatment enhances an anti-tumor immune response.

58. The method of any one of claims 48-57, wherein the oligomer complex is administered systemically.

59. The method of any one of claims 48-58, wherein the oligomer complex is administered locally.

60. The method of any one of claims 48-59, wherein the oligomer complex is administered intravenously, subcutaneously, intramuscularly, or intratumorally.

61. The method of any one of claims 48-60, wherein the oligomer complex is administered in a pharmaceutically acceptable formulation.

62. The method of any one of claims 48-61, wherein the oligomer complex comprises a scaffold having at least 90% sequence identity to any one of SEQ ID NOs: 1-3 and a Notch ligand having at least 90% sequence identity to SEQ ID NO: 4.

63. The method of any one of claims 48-62, wherein the oligomer complex is administered in combination with a second therapeutic agent.

64. The method of claim 63, wherein the second therapeutic agent comprises a chemotherapeutic agent, an immune checkpoint inhibitor, a cytokine, or a cell therapy.

65. The method of claim 64, wherein the cell therapy comprises adoptive transfer of T cells.

66. The method of claim 65, wherein the T cells are expanded or differentiated ex vivo using the oligomer complex prior to administration to the subject.

67. The method of any one of claims 48-66, wherein the treatment results in increased Notch pathway activation relative to a control.

68. The method of any one of claims 48-67, wherein the subject is a human.